Updates in Remibrutinib from ACAAI 2025

Recent presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 and European Academy of Dermatology and Venereology provided additional insights into the clinical and immunologic effects of remibrutinib in chronic spontaneous urticaria (CSU). In this video Shyam Joshi, MD, assistant professor of medicine in the Section of Allergy and Clinical Immunology at Oregon Health & Science University (OHSU) School of Medicine, breaks down Data demonstrating remibrutinib’s efficacy and safety across both major CSU subtypes—autoallergic (type I) and autoimmune (type IIb).

Analysis of the REMIX trials and additional substudies highlighted remibrutinib’s robust efficacy in patients previously unresponsive to omalizumab, the first FDA-approved biologic for CSU. Even among those who were refractory to this established treatment, remibrutinib achieved high response rates, supporting its utility as a second-line or rescue therapy in difficult-to-treat populations. This finding is of particular clinical significance, given the historical reliance on immunosuppressive agents for patients who failed standard therapies.

The breadth and quality of evidence presented at ACAAI 2025 solidify remibrutinib’s standing as a versatile agent within the CSU therapeutic armamentarium, with its oral administration, rapid onset of action, effective disease modification, and broad applicability positioning it as an integral component of individualized, guideline-driven CSU management. Ongoing updates to clinical practice recommendations are anticipated to further define remibrutinib’s role in routine care.